

Anti-IL-6/IFNb2 Antibody (Sirukumab)

Introduction B O

Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1k antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis.

Product parameters

Alternative Names	Plivensia, CNTO-136
Target Accession	P05231
Target	IL-6 / IFNb2
CAS number	1194585-53-9
Molecular Weight	144.58 kDa
Host	сно О АРЕхВО
Reactivity	Human Active Perfection, Explore the University
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	lgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human IL-6 His at 2 ug/mL can bind Anti-IL-6/IFNb2 Antibody (Sirukumab), EC50=0.0701 ug/mL
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.













APExBIO Technology www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com